Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.

It is important to determine better ways to identify which patients after 5 years of endocrine-therapy should continue it or switch to another form of therapy, explains Hayes.

According to Hayes, liquid biopsies are exciting and might have a role in determining which patients should be left on their current treatment.

Videos

Dr. Hayes on the Future of Biomarkers for Breast Cancer

Daniel F. Hayes, MD, professor of University of Michigan Comprehensive Cancer Center, discusses anti-estrogen therapy beyond 5 years in breast cancer.

One of the big questions facing the breast cancer field, Hayes says, is what to do about women who have made it to 5 years on an anti-estrogen therapy.

There are now 4 trials to suggest that continued anti-estrogen therapy beyond 5 years suppresses late recurrence.

Dr. Hayes Discusses Anti-Estrogen Therapy Beyond 5 Years in Breast Cancer

Daniel F. Hayes, MD, professor University of Michigan Comprehensive Cancer Center, discusses the use of tumor biomarker tests in breast cancer.

In the adjuvant setting, tumor biomarkers can provide an indication of the present of future behavior of a cancer. Multiple tests exist to measure these biomarkers, but the question among clinicians is: which test should be ordered?

In the adjuvant setting, 3 tumor biomarker tests—Prosigna, EndoPredict and Breast Cancer Index&mdash;have shown significant clinical utility, says Hayes. These multi-parameter assays measure either transcript or protein expression and have demonstrated analytic validity for prognosis in patients with ER-positive/HER2-negative, node-negative breast cancer.

View more from the St. Gallen's Breast Cancer Conference

Daniel F. Hayes, MD

Articles

Dr. Hayes on the Future of Biomarkers for Breast Cancer

Dr. Hayes Discusses Anti-Estrogen Therapy Beyond 5 Years in Breast Cancer

Dr. Hayes Discusses Tumor Biomarker Tests in Breast Cancer